OLVIG
BPMC

Oliver Lagore Vanvalin Investment Group’s Blueprint Medicines BPMC Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-70
Closed -$3.07K – 707
2022
Q4 		$3.07K Hold
70
– – ﹤0.01% 522
2022
Q3 		$5K Hold
70
– – ﹤0.01% 420
2022
Q2 		$4K Hold
70
– – ﹤0.01% 432
2022
Q1 		$4K Buy
+70
New +$5.03K ﹤0.01% 426

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's BPMC Position: Q1 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 70 shares — an estimated $3.07K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in BPMC in Q1 2022 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 70 Blueprint Medicines shares in Q1 2023, an estimated $3.07K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Blueprint Medicines in Q1 2022 and held it in 4 quarters.
  • Oliver Lagore Vanvalin Investment Group's Blueprint Medicines position peaked at $5K in Q3 2022.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q1 2023, filed 20 Jun 2023.